Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
- Published in:
- 2009
- By:
- Publication type:
- Journal Article
Works matching IS 01676997 AND DT 2009 AND VI 27 AND IP 5
Results: 13
1
2
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 5, p. 453, doi. 10.1007/s10637-008-9200-x
- By:
- Publication type:
- Article
3
Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 5, p. 402, doi. 10.1007/s10637-008-9185-5
- By:
- Publication type:
- Article
4
Artemisinin reduces human melanoma cell migration by down-regulating αVβ3 integrin and reducing metalloproteinase 2 production.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 5, p. 412, doi. 10.1007/s10637-008-9188-2
- By:
- Publication type:
- Article
5
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 5, p. 469, doi. 10.1007/s10637-008-9190-8
- By:
- Publication type:
- Article
6
Amino acetate functionalized Schiff base organotin(IV) complexes as anticancer drugs: synthesis, structural characterization, and in vitro cytotoxicity studies.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 5, p. 419, doi. 10.1007/s10637-008-9189-1
- By:
- Publication type:
- Article
7
Extracts of marine sponge Polymastia janeirensis induce oxidative cell death through a caspase-9 apoptotic pathway in human U138MG glioma cell line.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 5, p. 440, doi. 10.1007/s10637-008-9198-0
- By:
- Publication type:
- Article
8
Protective role of Withaferin-A on immunoexpression of p53 and bcl-2 in 7,12-dimethylbenz(a)anthracene-induced experimental oral carcinogenesis.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 5, p. 447, doi. 10.1007/s10637-008-9199-z
- By:
- Publication type:
- Article
9
Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 5, p. 476, doi. 10.1007/s10637-008-9191-7
- By:
- Publication type:
- Article
10
Mixed steroidal tetraoxanes induce apoptotic cell death in tumor cells.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 5, p. 432, doi. 10.1007/s10637-008-9197-1
- By:
- Publication type:
- Article
11
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 5, p. 482, doi. 10.1007/s10637-008-9217-1
- By:
- Publication type:
- Article
12
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 5, p. 461, doi. 10.1007/s10637-008-9210-8
- By:
- Publication type:
- Article
13
Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 5, p. 393, doi. 10.1007/s10637-008-9183-7
- By:
- Publication type:
- Article